$245 Million is the total value of Altium Capital Management LP's 68 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CPRX | CATALYST PHARMACEUTICALS INC | $7,745,000 | -2.8% | 500,000 | 0.0% | 3.16% | +0.2% | |
| CLXPF | CYBIN INC | $3,781,395 | -34.5% | 13,953,488 | 0.0% | 1.54% | -32.4% | |
| ORIC | ORIC PHARMACEUTICALS INC | $2,863,350 | -48.6% | 405,000 | 0.0% | 1.17% | -47.0% | |
| KPTI | KARYOPHARM THERAPEUTICS INC | $642,024 | -42.5% | 740,000 | 0.0% | 0.26% | -40.7% | |
| FATBW | FAT BRANDS INC*w exp 07/16/202 | $569,000 | -41.6% | 200,000 | 0.0% | 0.23% | -39.7% | |
| NEXGEL INC*w exp 12/01/202 | $98,325 | -39.3% | 225,000 | 0.0% | 0.04% | -37.5% | ||
| WEARABLE DEVICES LTD*w exp 09/14/202 | $70,015 | -36.0% | 1,411,600 | 0.0% | 0.03% | -32.6% | ||
| ONFOLIO HOLDINGS INC*w exp 01/02/202 | $49,760 | +512.8% | 200,000 | 0.0% | 0.02% | +566.7% | ||
| ROCKET PHARMACEUTICALS INC*w exp 09/02/202 | $44,406 | -79.7% | 731,561 | 0.0% | 0.02% | -79.3% | ||
| NEXALIN TECHNOLOGY INC*w exp 99/99/999 | $35,700 | +713.4% | 105,000 | 0.0% | 0.02% | +650.0% | ||
| MOBIX LABS INC*w exp 99/99/999 | $26,820 | -14.9% | 150,000 | 0.0% | 0.01% | -8.3% | ||
| NLSPW | NLS PHARMACEUTICS LTD*w exp 02/02/202 | $6,900 | +0.3% | 200,000 | 0.0% | 0.00% | 0.0% | |
| CEA INDUSTRIES INC*w exp 02/11/202 | $3,750 | +15.4% | 250,000 | 0.0% | 0.00% | +100.0% | ||
| WESTERN ACQSTN VENTURES CORP*w exp 99/99/999 | $3,660 | -14.4% | 100,000 | 0.0% | 0.00% | -50.0% | ||
| JEFFS BRANDS LTD*w exp 99/99/999 | $2,198 | -45.2% | 68,681 | 0.0% | 0.00% | -50.0% | ||
| CONDUIT PHARMACEUTICALS INC*w exp 09/22/202 | $1,550 | -74.2% | 100,000 | 0.0% | 0.00% | -50.0% | ||
| CINGULATE INC*w exp 12/10/202 | $2,916 | -48.8% | 270,000 | 0.0% | 0.00% | -50.0% | ||
| COLISEUM ACQUISITION CORP*w exp 08/22/202 | $1,417 | -24.2% | 28,333 | 0.0% | 0.00% | 0.0% | ||
| BITCOIN DEPOT INC*w exp 06/30/202 | $2,365 | -50.2% | 50,000 | 0.0% | 0.00% | -50.0% | ||
| SURROZEN INC*w exp 08/01/203 | $1,365 | -59.9% | 82,233 | 0.0% | 0.00% | 0.0% | ||
| TC BIOPHARM HOLDINGS PLC*w exp 02/10/202 | $235 | -37.5% | 18,823 | 0.0% | 0.00% | – | ||
| SELINA HOSPITALITY PLC*w exp 10/27/202 | $1,101 | +55.1% | 101,439 | 0.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FAT BRANDS INC | 15 | Q2 2024 | 0.6% |
| XTANT MED HLDGS INC | 13 | Q2 2024 | 6.2% |
| SURROZEN INC | 12 | Q2 2024 | 0.0% |
| ADMA BIOLOGICS INC | 11 | Q2 2024 | 6.9% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.9% |
| INSMED INC | 11 | Q2 2024 | 5.2% |
| NEXGEL INC | 11 | Q2 2024 | 0.1% |
| NOCTURNE ACQUISITION CORP | 11 | Q1 2024 | 0.1% |
| CINGULATE INC | 11 | Q2 2024 | 0.1% |
| NLS PHARMACEUTICS LTD | 11 | Q2 2024 | 0.0% |
View Altium Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CEMTREX INC | May 08, 2024 | 36,984 | 10.0% |
| Sunshine Biopharma, Inc | February 21, 2024 | 3,727,984 | 10.0% |
| Evoke Pharma Inc | February 20, 2024 | 822,986 | 9.7% |
| ALIMERA SCIENCES INC | February 13, 2024 | 2,660,000 | 5.0% |
| Cyclacel Pharmaceuticals, Inc. | February 13, 2024 | 37,982 | 5.0% |
| GRI BIO, Inc. | February 13, 2024 | 1,269,210 | 5.0% |
| Marpai, Inc.Sold out | February 13, 2024 | 0 | 0.0% |
| NovaBay Pharmaceuticals, Inc. | February 13, 2024 | 67,457 | 5.0% |
| Volcon, Inc. | February 13, 2024 | 1,666,665 | 9.9% |
| Xtant Medical Holdings, Inc. | February 13, 2024 | 8,027,593 | 6.2% |
View Altium Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-09-26 |
| N-PX | 2024-08-26 |
| SC 13G | 2024-08-16 |
| 13F-HR | 2024-08-15 |
| SC 13G | 2024-08-09 |
| SC 13G | 2024-08-09 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-08 |
| SC 13G | 2024-02-21 |
| SC 13G | 2024-02-20 |
View Altium Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.